Caribou Biosciences filings document a clinical-stage CRISPR genome-editing biopharmaceutical company focused on allogeneic CAR-T therapies. Recent 8-K reports furnish quarterly and annual financial results, cash and operating-plan disclosures, business updates, and Regulation FD disclosures covering vispa-cel and CB-011 clinical and FDA-related developments.
Proxy materials describe annual meeting matters, board elections, auditor ratification, and proposed charter governance changes for the Delaware corporation. Other event filings record public-company status matters, including Nasdaq bid-price compliance notices and product-candidate regulatory designations.
Caribou Biosciences reported first-quarter 2026 results showing a narrower net loss as it continues to advance its allogeneic CAR-T pipeline. Licensing and other revenue was $2.4 million, while research and development and general and administrative expenses fell to $20.6 million and $8.1 million, respectively.
Net loss improved to $25.1 million from $40.0 million a year earlier, and operating cash use declined to $27.0 million. As of March 31, 2026, the company held $118.6 million in cash, cash equivalents, and marketable securities, which management believes will fund operations for at least 12 months while it prepares a pivotal phase 3 trial for vispa‑cel and expands CB‑011 development.
Caribou Biosciences reported first quarter 2026 results and highlighted key progress in its allogeneic CAR-T programs. Licensing and other third-party revenue was $2.4 million for the three months ended March 31, 2026, essentially unchanged from $2.4 million a year earlier.
Research and development expenses fell to $20.6 million from $35.5 million, and general and administrative expenses declined to $8.1 million from $9.7 million, reflecting prior workforce reductions and pipeline prioritization. Net loss narrowed to $25.1 million, or $0.26 per share, compared with a $40.0 million loss, or $0.43 per share, in 2025.
Caribou ended the quarter with $118.6 million in cash, cash equivalents, and marketable securities and expects this to fund its current operating plan, including CB-011 dose expansion and start-up activities for the planned pivotal vispa-cel trial, into the second half of 2027. The company also reported FDA alignment on the pivotal ANTLER-3 phase 3 design for vispa-cel and RMAT designation for CB-011 based on promising phase 1 data.
Caribou Biosciences, Inc. filed an amendment to its definitive proxy statement to correct a clerical error in the reported shares outstanding and to reconfirm details for its virtual 2026 Annual Meeting. The corrected shares outstanding on the record date are 98,258,898 as of April 20, 2026. The annual meeting is scheduled for June 17, 2026 in a virtual format and includes voting on (1) election of three Class II directors, (2) ratification of Deloitte & Touche LLP as independent auditors, (3) approval of an amendment to permit officer exculpation under Delaware law, and (4) an adjournment proposal to permit further solicitation if needed. The amendment notes that percentages in the beneficial ownership table were updated to reflect the corrected outstanding share count and states there are no other material changes to the originally filed proxy statement.
Caribou Biosciences, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, describing its clinical-stage CRISPR chRDNA genome-editing platform and two lead allogeneic CAR-T product candidates: vispa-cel (anti-CD19) and CB-011 (anti-BCMA). The filing summarizes clinical results and development plans, regulatory designations, manufacturing strategy, collaborations, intellectual property, and a workforce reduction announced April 24, 2025, as part of a pipeline prioritization.
The filing reports clinical data cutoffs for vispa-cel and CB-011, ongoing engagement with the FDA on a planned pivotal phase 3 for vispa-cel, a strategic investment and information-rights arrangement with Pfizer, patent and license positions, and key risks including continued operating losses and the need for additional financing.
Caribou Biosciences, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 17, 2026. Investors will elect three Class II directors to serve until the 2029 meeting, ratify Deloitte & Touche LLP as auditor for 2026, and consider an amendment to the certificate of incorporation to add officer exculpation to the fullest extent permitted by Delaware law. Stockholders will also vote on a proposal to adjourn the meeting, if needed, to secure sufficient support for the charter amendment or to reach a quorum. The proxy discloses that 98,682,370 common shares are entitled to vote and provides detailed information on board composition, independence, executive roles, and 2024–2025 executive compensation, including salaries, cash bonuses, and equity awards.
Caribou Biosciences has scheduled a virtual 2026 Annual Meeting of Stockholders for June 17, 2026 at 7:30 a.m. Pacific to vote on director elections, ratification of Deloitte & Touche LLP as auditor, an Officer Exculpation Proposal amending the certificate of incorporation, and an adjournment proposal. The Board set the record date as April 20, 2026. Materials including the proxy statement and the 2025 Annual Report are available at www.proxyvote.com and shareholders may vote online, by telephone, mail, or remotely at the virtual meeting.
Caribou Biosciences reported that the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CB-011, its allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma. The designation is based on phase 1 CaMMouflage trial dose-escalation data in a 12-patient BCMA-naïve cohort, which showed a 92% overall response rate, a 75% complete response or better rate, and 91% minimal residual disease negativity at the recommended expansion dose. Forty-eight patients have been treated in dose escalation, and the ongoing dose expansion is testing a 450x106 CAR-T cell dose in both BCMA-naïve and BCMA-exposed patients, with additional data expected in 2026. CB-011 has shown a manageable safety profile, with common treatment-emergent adverse events including neutropenia, anemia, thrombocytopenia, infections, and cytokine release syndrome.
Caribou Biosciences, Inc. is a clinical-stage genome-editing company using its proprietary CRISPR chRDNA technology to develop off‑the‑shelf CAR‑T cell therapies for blood cancers. As of June 30, 2025, non‑affiliate equity market value was $112.5 million, and 96,637,202 common shares were outstanding as of February 27, 2026.
The company’s two lead allogeneic CAR‑T programs are vispa‑cel for relapsed or refractory B‑cell non‑Hodgkin lymphoma and CB‑011 for relapsed or refractory multiple myeloma. Vispa‑cel has U.S. FDA RMAT, fast track, and orphan drug designations, while CB‑011 has fast track and orphan designations.
On April 24, 2025, Caribou announced a strategic pipeline prioritization, discontinuing its GALLOP vispa‑cel lupus trial, the AMpLify CB‑012 trial in acute myeloid leukemia, and preclinical research, and reducing its workforce by approximately 32%. Caribou also highlights a $25.0 million equity investment by Pfizer and multiple licensing agreements supporting its intellectual property portfolio.
Caribou Biosciences reported fourth quarter and full year 2025 results while highlighting progress in its allogeneic CAR-T pipeline. Licensing and collaboration revenue was $3.9 million in Q4 2025 and $11.2 million for 2025, up from $2.1 million and $10.0 million in 2024, mainly from prior IP licenses.
Research and development expenses fell to $109.4 million for 2025 from $130.2 million in 2024, and general and administrative expenses declined to $37.9 million from $46.5 million, reflecting workforce reductions and pipeline prioritization. The company recorded $21.3 million of non-recurring, non-cash impairment charges in 2025.
GAAP net loss was $26.5 million (or $0.28 per share) in Q4 2025 and $148.1 million (or $1.59 per share) for 2025. Non-GAAP net loss for 2025, excluding impairment charges, was $126.8 million (or $1.36 per share). Caribou held $142.8 million in cash, cash equivalents, and marketable securities as of December 31, 2025 and expects this to fund its current operating plan, including CB-011 dose expansion and certain start-up activities for a planned vispa-cel pivotal trial, into 2H 2027.
Caribou Biosciences, Inc. Chief Technology Officer Timothy P. Kelly reported an open-market sale of 6,228 shares of common stock at $1.93 per share. After this February 25, 2026 transaction, he directly owns 73,125 shares of Caribou Biosciences common stock.